Disease status prediction on ACE (test)
64.4AccuracyNeuroPathX
Evaluation results
| Method | Links | ||||
|---|---|---|---|---|---|
| NeuroPathXvalidation=10-fold cross-validation2025.08 | 64.4 | 56.2 | 76.2 | 68 | |
| NeuroPathX w/o L_spvalidation=10-fold cross-validation, ablation=removed sparsity loss2025.08 | 62 | 74.3 | 74.3 | 66.2 | |
| NeuroPathX w/o L_pathvalidation=10-fold cross-validation, ablation=removed pathway similarity loss2025.08 | 58.6 | 51.2 | 69 | 65.2 | |
| CALM2026.07 | 57.2 | 58.3 | 56.2 | 60.6 | |
| Ablation -LcmmdConfiguration=Omitting distributional loss Lcmmd2026.07 | 57 | 56.8 | 54.8 | 58.5 | |
| G-MINDvalidation=10-fold cross-validation2025.08 | 56.9 | 59.3 | 56.7 | 61.8 | |
| Ablation -LconConfiguration=Omitting contrastive loss Lcon2026.07 | 56.8 | 57.5 | 55.7 | 59.8 | |
| Ablation LOTConfiguration=Optimal transport with global Sinkhorn divergence2026.07 | 56.7 | 57.3 | 56.8 | 59.9 | |
| CCAvalidation=10-fold cross-validation2025.08 | 55.7 | 90 | 6 | 47.8 | |
| SurvPATHvalidation=10-fold cross-validation2025.08 | 53.8 | 46.9 | 63.8 | 53.4 | |
| G-MIND2026.07 | 51.8 | 53.3 | 49 | 54 | |
| UNSEEN2026.07 | 49.9 | 49 | 51 | 52.2 | |
| SUE2026.07 | 48.6 | 43 | 54.9 | 47.8 |